AbbVie Total Cost of Revenue decreased by 7.3% to $4.22B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.4%, from $4.00B to $4.22B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows relatively stable performance with a 1.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $4.52B | $4.39B | $4.32B | $4.05B | $4.17B | $5.02B | $4.17B | $3.99B | $4.24B | $6.49B | $5.70B | $4.09B | $4.20B | $4.21B | $4.40B | $4.00B | $4.35B | $5.30B | $4.55B | $4.22B |
| QoQ Change | — | -2.9% | -1.6% | -6.2% | +2.9% | +20.4% | -17.0% | -4.4% | +6.4% | +52.9% | -12.0% | -28.2% | +2.6% | +0.2% | +4.4% | -9.0% | +8.6% | +22.0% | -14.2% | -7.3% |
| YoY Change | — | — | — | — | -7.8% | +14.4% | -3.5% | -1.6% | +1.7% | +29.1% | +36.8% | +2.7% | -0.9% | -35.1% | -22.9% | -2.2% | +3.4% | +25.9% | +3.5% | +5.4% |